| (USD) | Jun 2023 | Q/Q |
|---|---|---|
| Revenue | 317.8MM | +3% |
| Gross Profit | 228.3MM | +3% |
| Cost Of Revenue | 89.5MM | +4% |
| Operating Income | 12.5MM | - |
| Operating Expenses | 210.3MM | -2% |
| Net Income | 7.4MM | -827% |
| R&D | 28.7MM | +17% |
| G&A | 163.9MM | -7% |
| Amortization | 8MM | -9% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Dell upgraded, Starbucks downgraded: Wall Street's top analyst calls
NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it received a lot of attention from a...
Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle.
S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1:
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
NuVasive (NUVA) delivered earnings and revenue surprises of 0% and 1.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023.
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market.